Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 May;45(5):1438-43.
doi: 10.1128/AAC.45.5.1438-1443.2001.

Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy

J Mittler  1 , P Essunger, G J Yuen, N Clendeninn, M Markowitz, A S Perelson
Affiliations

Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy

J Mittler et al. Antimicrob Agents Chemother. 2001 May.

Abstract

We calculated the relative efficacy of treatment, defined as the rate of decline of virus levels in plasma during treatment relative to the rate of decline during highly potent combination therapy, in human immunodeficiency virus type 1 (HIV-1) patients treated for 56 days with different doses of the protease inhibitor nelfinavir. Relative efficacies based on the rate of decline of HIV-1 RNA levels in plasma over the first 14 to 21 days correlated with drug dose and viral load reduction by day 56. Calculation of relative treatment efficacies over the first 2 to 3 weeks of treatment can allow rapid assessment of new antiretroviral agents and dosing regimens, reducing the need to keep subjects in clinical trials on monotherapy for prolonged periods of time. Relative efficacy may also serve as a measure of treatment efficacy in patients in initiating established therapies.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Mean reduction in HIV-1 RNA in plasma during the first 2 months for the five daily doses of nelfinavir.
FIG. 2
FIG. 2
Correlation between reduction in HIV-1 RNA after 2 months of therapy, log(V56/V0), and two measures of relative efficacy, ɛ4,14 and ɛ4,21. For the five subjects in which monotherapy was modified at day 28 due to a failure to achieve a 10-fold reduction in viral load, we used log(V28/V0) in place of log(V56/V0). As described in the text, we believe this substitution is conservative, because virus will usually continue to increase following a viral load rebound in patients who remain on Pr inhibitor monotherapy. Symbols are defined as in Fig. 1.
FIG. 3
FIG. 3
Mean drug concentration in plasma during the first 4 weeks for each of the six dosage regimens. Error bars indicate 95% confidence intervals.
See this image and copyright information in PMC

References

    1. Angel J B, Kumar A, Parato K, Filion L G, Diaz-Mitoma F, Daftarian P, Pham B, Sun E, Leonard J M, Cameron D W. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis. 1998;177:898–904. - PubMed
    1. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother. 1998;42:2775–2783. - PMC - PubMed
    1. Bonhoeffer S, May R M, Shaw G M, Nowak M A. Virus dynamics and drug therapy. Proc Natl Acad Sci USA. 1997;94:6971–6976. - PMC - PubMed
    1. Cao Y, Ho D D, Todd J, Kokka R, Urdea M, Lifson J D, Piatak M, Jr, Chen S, Hahn B H, Saag M S. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retrovir. 1995;11:353–361. - PubMed
    1. Chiesi A, Mocroft A, Dally L G, Miller V, Katlama C, Ledergerber B, Pedersen C, Phillips A N, Arcieri R, Lundgren J D. Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. AIDS. 1999;13:2281–2288. - PubMed

Publication types

LinkOut - more resources